公开(公告)号：US20200031761A1

公开(公告)日：2020-01-30

申请号：US16365532

申请日：2019-03-26

Applicant: ID4PHARMA, LLC

Inventor： Xiang-Qun Xie ,  Garson David Roodman ,  Kyaw-Zeyar Myint ,  Noriyoshi Kurihara

IPC: C07C229/36 ,  C07D309/40 ,  C07C211/50 ,  C07C317/34 ,  C07C217/58 ,  C07C217/76 ,  C07C219/06 ,  C07D241/44 ,  C07C229/14 ,  C07D487/04 ,  C07C235/48 ,  C07C251/76 ,  A61K31/137 ,  A61K31/351 ,  A61K31/495 ,  A61K31/519 ,  A61K31/15 ,  A61K31/498 ,  A61K45/06 ,  C07C249/16 ,  C07D309/32 ,  C07D475/08 ,  C12N5/09 ,  A61K31/216

Abstract: A method for treating a p62-mediated disease (e.g., multiple myeloma) in a subject, the method comprising administering to the subject a therapeutically effective amount of at least one p62-ZZ inhibitor compound.

公开(公告)号：US11739053B2

公开(公告)日：2023-08-29

申请号：US16365532

申请日：2019-03-26

Applicant: ID4PHARMA, LLC

Inventor： Xiang-Qun Xie ,  Garson David Roodman ,  Kyaw-Zeyar Myint ,  Noriyoshi Kurihara

IPC: C07C229/36 ,  C07D309/40 ,  C07C211/50 ,  C07C317/34 ,  C07C217/58 ,  C07C217/76 ,  C07C219/06 ,  C07D241/44 ,  C07C229/14 ,  C07D487/04 ,  C07C235/48 ,  C07C251/76 ,  A61K31/137 ,  A61K31/351 ,  A61K31/495 ,  A61K31/519 ,  A61K31/15 ,  A61K31/498 ,  A61K45/06 ,  C07C249/16 ,  C07D309/32 ,  C07D475/08 ,  C12N5/09 ,  A61K31/216

CPC classification number: C07C229/36 ,  A61K31/137 ,  A61K31/15 ,  A61K31/216 ,  A61K31/351 ,  A61K31/495 ,  A61K31/498 ,  A61K31/519 ,  A61K45/06 ,  C07C211/50 ,  C07C217/58 ,  C07C217/76 ,  C07C219/06 ,  C07C229/14 ,  C07C235/48 ,  C07C249/16 ,  C07C251/76 ,  C07C317/34 ,  C07D241/44 ,  C07D309/32 ,  C07D309/40 ,  C07D475/08 ,  C07D487/04 ,  C12N5/0693

Abstract: A method for treating a p62-mediated disease (e.g., multiple myeloma) in a subject, the method comprising administering to the subject a therapeutically effective amount of at least one p62-ZZ inhibitor compound.

公开(公告)号：US20160031799A1

公开(公告)日：2016-02-04

申请号：US14727710

申请日：2015-06-01

Applicant: ID4PHARMA, LLC

Inventor： Xiang-Qun Xie ,  Garson David Roodman ,  Kyaw-Zeyar Myint ,  Noriyoshi Kurihara

IPC: C07C229/36 ,  A61K31/216 ,  A61K45/06 ,  C07C217/58 ,  A61K31/137

CPC classification number: C07C229/36 ,  A61K31/137 ,  A61K31/15 ,  A61K31/216 ,  A61K31/351 ,  A61K31/495 ,  A61K31/498 ,  A61K31/519 ,  A61K45/06 ,  C07C211/50 ,  C07C217/58 ,  C07C217/76 ,  C07C219/06 ,  C07C229/14 ,  C07C235/48 ,  C07C249/16 ,  C07C251/76 ,  C07C317/34 ,  C07D241/44 ,  C07D309/32 ,  C07D309/40 ,  C07D475/08 ,  C07D487/04 ,  C12N5/0693

Abstract: A method for treating a p62-mediated disease (e.g., multiple myeloma) in a subject, the method comprising administering to the subject a therapeutically effective amount of at least one p62-ZZ inhibitor compound.